Posted by Michael Wonder on 11 Jul 2022
Anthos Therapeutics announces that abelacimab has received FDA fast track designation for the treatment of thrombosis associated with cancer
11 July 2022 - Abelacimab is a dual-acting fully human monoclonal antibody targeting both factor XI and Factor XIa with high affinity and selectivity.
Anthos Therapeutics today announced that the U.S. FDA has granted fast track designation to its investigational factor XI inhibitor, abelacimab, for the treatment of thrombosis associated with cancer.
